Good morning bulls!
This month’s winner is Omeros Corporation (OMER: $19.58).
Summary: OMER is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for large-market, and treatments for central nervous system disorders. Their first drug OMIDIRA was launched in 2015, and currently they have several clinical and pre-clinical drugs in the pipeline.
Why we like it: Their clinical stage drug OMS721 (beginning its second phase 3 trial this year) was granted ‘Breakthrough Therapy Designation’ by the FDA this Tuesday. In short, this means that they will have an accelerated approval process! While the news was already a great catalyst in itself (price jumped up 17%), OMER will also be holding its Annual Shareholder Meeting this Friday at 10:00am PT! Moreover, OMER has solid financials with a consistent year-on-year sales growth, and improving operational performance.